Rapt Therapeutics, Inc. (RAPT)
Stock Price:
$32.51 USD
0.58 (1.82%)
Updated Oct 27, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
795.48M |
| Revenue (ttm) |
2.21M |
| Net Income (ttm) |
-48.71M |
| Shares Out |
24.47M |
| EPS (ttm) |
-3.07 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 27, 2020 |
| Last Price |
$32.51 |
| Previous Close |
$31.93 |
| Change ($) |
0.58 |
| Change (%) |
1.82% |
| Day's Open |
31.17 |
| Day's Range |
30.42 - 32.88 |
| Day's Volume |
221,773 |
| 52-Week Range |
10.52 - 51.21 |
More Stats
| Market Cap |
795.48M |
| Enterprise Value |
662.53M |
| Earnings Date (est) |
Dec 9, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
24.47M |
| Float |
15.68M |
| EPS (basic) |
16.78 |
| EPS (diluted) |
-3.07 |
| FCF / Share |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
882,388 |
| Short Ratio |
1.31 |
| Short % of Float |
5.63% |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
359.62 |
| PB Ratio |
7.80 |
| Revenue |
2.21M |
| Operating Income |
-48.68M |
| Net Income |
-48.71M |
| Free Cash Flow |
n/a |
| Net Cash |
132.95M |
| Net Cash / Share |
5.43 |
| Gross Margin |
100.00% |
| Operating Margin |
-2,200.63% |
| Profit Margin |
-2,202.20% |
| FCF Margin |
n/a |
| ROA |
-29.28% |
| ROE |
-53.35% |
| ROIC |
-130.20% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (6)
| Buy |
6 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$44.33*
(36.36% upside)
Low
38.0
Current: $32.51
High
51.0
Target: 44.33
*Average 12-month price target from 6 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 |
|---|
| Revenue | - | - | - |
| Operating Income | -43.63 | -36.95 | -29.33 |
| Net Income | -43.00 | -36.15 | -29.12 |
| Shares Outstanding | 4.35 | 0.62 | 0.43 |
| Earnings Per Share | -9.89 | -58.09 | -67.45 |
| Operating Cash Flow | -35.47 | -32.95 | -27.12 |
| Capital Expenditures | -0.84 | -3.50 | -1.12 |
| Free Cash Flow | -36.32 | -36.45 | -28.25 |
| Cash & Equivalents | 77.38 | 63.80 | 47.52 |
| Net Cash / Debt | 77.38 | 63.80 | 47.52 |
| Assets | 84.60 | 69.61 | 50.39 |
| Liabilities | 11.48 | 167 | 113 |
| Book Value | 73.12 | -97.11 | -62.41 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Rapt Therapeutics, Inc. |
| Country |
United States |
| Employees |
71 |
| CEO |
Brian Russell Wong |
Stock Information
| Ticker Symbol |
RAPT |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: RAPT |
| IPO Date |
October 31, 2019 |
Description
RAPT Therapeutics, a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead oncology drug candidate is FLX475, an oral small molecule C-C motif chemokine receptor 4 antagonist that is in the Phase 2 portion of a Phase 1/2 clinical trial to evaluate as a monotherapy and in combination with pembrolizumab in patients with various types of charged tumors. The company's lead inflammation drug candidate is RPT193 to selectively inhibit the migration of type 2 T helper cells into allergically-inflamed tissues. It is also pursuing a range of targets, including general control nonderepressible 2 and hematopoietic progenitor kinase 1 that are in the discovery stage of development. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was founded in 2015 and is headquartered in South San Francisco, California.